Przejdź do treściGeneral Medical Discoveries · Human study — phase 2
Researchers tested teclistamab in people with high-risk smoldering multiple myeloma, a precursor condition that has not yet caused the typical organ damage of active multiple myeloma but carries a substantial risk of progression. In this randomized phase 2 study, teclistamab produced much deeper responses than lenalidomide plus dexamethasone; at two years, progression-free survival was estimated at 92% with teclistamab and 49% with the comparison treatment. The result is important because it explores whether disease can be intercepted before symptomatic myeloma develops. An orthopaedic surgeon interpreting this haematology study should note that it was still small—59 people were treated—and that longer follow-up is needed to establish durability, overall-survival effects and longer-term safety. Teclistamab remains experimental in this setting, and these findings do not mean that every person with smoldering myeloma should receive treatment.
Source: Nadeem O, Cordas dos Santos DM, Magidson S, et al. Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial. Nature Medicine. Published online 11 September 2026. DOI: 10.1038/s41591-026-04642-w. ClinicalTrials.gov: NCT05469893. Verified 15 September 2026 against the open-access full article and PubMed record.
Polish version · More General Medical Discoveries
Content prepared by: Tomasz Poboży - orthopaedic surgeon.